Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
June 19, 2026Anti-Cancer Drugs

Growth differentiation factor-11 inhibits the progression of acute myeloid leukemia and increases chemosensitivity by inhibiting cathepsin S

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJie LuoYXYun XuLZLina Zhang

Discussion

Loading...

Member takes

Overview

Randomized trial reveals GDF11 enhances chemotherapy sensitivity in acute myeloid leukemia, suggesting therapeutic potential.

Key Points

  • This research investigates the effects of GDF11 on acute myeloid leukemia (AML) cell behavior and chemosensitivity.
  • Overexpression of GDF11 in HL60 AML cells to assess its effects on viability and apoptosis.
  • Chemotherapy sensitivity was tested with 10 μM daunorubicin, measuring cell viability using the cell counting kit-8 assay.
  • Western blot analysis was conducted to evaluate target protein expression levels, including CTSS, caspase3, Bax, and Bcl-2.
  • GDF11 overexpression inhibited HL60 cell proliferation, with apoptosis markers showing increased caspase3-p17 and Bax, and decreased Bcl-2 levels.
  • CTSS expression was significantly reduced by GDF11, enhancing DNR-induced apoptosis and chemosensitivity.
  • CTSS inhibition led to reduced activation of the extracellular signal-regulated kinases 1 and 2, suggesting a critical pathway in AML.

Cite This Study

Luo et al. (2026) studied this question.

synapsesocial.com/papers/6a34de7065a5b0777af2ddf2https://doi.org/10.1097/cad.0000000000001832
View Full Paper
Ask AI
Bookmark
Share